ArticleAllergy2024

Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.

Tanawin Nopsopon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.